146 related articles for article (PubMed ID: 30053908)
21. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
22. High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model.
Peng M; Su Q; Zeng Q; Li L; Liu Z; Xue L; Cheng Y; Huang Y; Tao T; Lv H; Li X; Tao X; Guo P; Chen AF; Yang X
Oncotarget; 2016 Feb; 7(8):9102-17. PubMed ID: 26802022
[TBL] [Abstract][Full Text] [Related]
23. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
[TBL] [Abstract][Full Text] [Related]
24. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
Segovia-Mendoza M; Díaz L; González-González ME; Martínez-Reza I; García-Quiroz J; Prado-Garcia H; Ibarra-Sánchez MJ; Esparza-López J; Larrea F; García-Becerra R
J Steroid Biochem Mol Biol; 2015 Apr; 148():122-31. PubMed ID: 25510900
[TBL] [Abstract][Full Text] [Related]
25. Baicalin, a Chinese Herbal Medicine, Inhibits the Proliferation and Migration of Human Non-Small Cell Lung Carcinoma (NSCLC) Cells, A549 and H1299, by Activating the SIRT1/AMPK Signaling Pathway.
You J; Cheng J; Yu B; Duan C; Peng J
Med Sci Monit; 2018 Apr; 24():2126-2133. PubMed ID: 29632297
[TBL] [Abstract][Full Text] [Related]
26. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
[TBL] [Abstract][Full Text] [Related]
27. The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells.
Orecchioni S; Reggiani F; Talarico G; Mancuso P; Calleri A; Gregato G; Labanca V; Noonan DM; Dallaglio K; Albini A; Bertolini F
Int J Cancer; 2015 Mar; 136(6):E534-44. PubMed ID: 25196138
[TBL] [Abstract][Full Text] [Related]
28. AICAR Induces Apoptosis and Inhibits Migration and Invasion in Prostate Cancer Cells Through an AMPK/mTOR-Dependent Pathway.
Su CC; Hsieh KL; Liu PL; Yeh HC; Huang SP; Fang SH; Cheng WC; Huang KH; Chiu FY; Lin IL; Huang MY; Li CY
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987073
[TBL] [Abstract][Full Text] [Related]
29. Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR.
Veiga SR; Ge X; Mercer CA; Hernández-Álvarez MI; Thomas HE; Hernandez-Losa J; Ramón Y Cajal S; Zorzano A; Thomas G; Kozma SC
Clin Cancer Res; 2018 Aug; 24(15):3767-3780. PubMed ID: 29691292
[No Abstract] [Full Text] [Related]
30. IKK promotes cytokine-induced and cancer-associated AMPK activity and attenuates phenformin-induced cell death in LKB1-deficient cells.
Antonia RJ; Baldwin AS
Sci Signal; 2018 Jul; 11(538):. PubMed ID: 29991651
[TBL] [Abstract][Full Text] [Related]
31. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
32. Biguanides Metformin and Phenformin Generate Therapeutic Effects via AMP-Activated Protein Kinase/Extracellular-Regulated Kinase Pathways in an In Vitro Model of Graves' Orbitopathy.
Han YE; Hwang S; Kim JH; Byun JW; Yoon JS; Lee EJ
Thyroid; 2018 Apr; 28(4):528-536. PubMed ID: 29589999
[TBL] [Abstract][Full Text] [Related]
33. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
Gu HR; Park SC; Choi SJ; Lee JC; Kim YC; Han CJ; Kim J; Yang KY; Kim YJ; Noh GY; No SH; Jeong JH
Clin Mol Hepatol; 2015 Mar; 21(1):49-59. PubMed ID: 25834802
[TBL] [Abstract][Full Text] [Related]
34. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
35. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
[TBL] [Abstract][Full Text] [Related]
36. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
[TBL] [Abstract][Full Text] [Related]
37. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
[TBL] [Abstract][Full Text] [Related]
38. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
39. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.
Shrader M; Pino MS; Lashinger L; Bar-Eli M; Adam L; Dinney CP; McConkey DJ
Cancer Res; 2007 Feb; 67(4):1430-5. PubMed ID: 17308080
[TBL] [Abstract][Full Text] [Related]
40. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
